Rational use of pharmacogenetic and pharmacogenomic data in post marketing innovation
- At: 2004 FIP Congress in New Orleans (USA)
- Type: Presentation
- By: DAWSON, Bill (Bionet Ltd, Alton, Hants, United Kingdom)
Many medicines do not work equally well in the total patient population for a given indication. Modern genomic science suggests that this may be a result of variation in specific drug targets where single nucleotide polymorphisms may change responsiveness. In addition, the ability of any species to handle xenobiotics has a genetic basis, which.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.